Health Condition 1: L509- Urticaria, unspecified
Conditions
Interventions
Intervention1: Vitamin D supplementation: Type: Vitamin supplement
Dosage Form: Oral capsule
Dosage: 60,000 IU
Route of Administration: Oral
Frequency: Once weekly
Total Duration of Therapy: 8 weeks
C
Sponsors
Nadar Saundarya Chandrasekar
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 to 65 years 2. Clinically diagnosed with chronic urticaria with symptoms for 6 weeks or more 3. Documented Vitamin D deficiency with serum 25 OH D level less than 20 ng per mL 4. Willing to provide written informed consent 5. Willing to comply with the study protocol and follow up visits
Exclusion criteria
Exclusion criteria: 1. Patients with physical urticarias (cold, cholinergic, pressure-induced, etc.) as primary diagnosis. 2. Patients with autoimmune connective tissue disease, systemic vasculitis, or other chronic inflammatory conditions. 3. Patients who have received Vitamin D supplementation in the past 3 months. 4. Patients on systemic immunosuppressive therapy in the last 4 weeks. 5. Pregnant or lactating women. 6. Patients with severe hepatic, renal, or endocrine dysfunction. 7. Known hypersensitivity to Vitamin D preparations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of Vitamin D supplementation on clinical severity of chronic urticaria in Vitamin D-deficient patients, as measured by the Urticaria Activity Score (UAS7).Timepoint: Eligible patients will be given Vitamin D supplementation (60,000 IU orally once weekly for 8 weeks). During the supplementation period, participants will be monitored for changes in relapse frequency, clinical severity (UAS7), quality of life (DLQI), serum Vitamin D levels (baseline and at 8 weeks), and adverse events. | — |
Secondary
| Measure | Time frame |
|---|---|
| -To evaluate the effect of Vitamin D supplementation on serum Vitamin D levels and other biochemical markers. -To assess improvement in quality of life using the Dermatology Life Quality Index (DLQI). -To monitor the safety and tolerability of Vitamin D supplementation. Timepoint: Eligible patients will be given Vitamin D supplementation (60,000 IU orally once weekly for 8 weeks). During the supplementation period, participants will be monitored for changes in relapse frequency, clinical severity (UAS7), quality of life (DLQI), serum Vitamin D levels (baseline and at 8 weeks), and adverse events. | — |
Countries
India
Contacts
Public ContactNadar Saundarya Chandrasekar
Chettinad Hospital and Research Institute
Outcome results
None listed